Rapid Build of HIV Related Protective Barriers

National Center for AIDS/STD Control and Prevention, China CDC

Status: Unknown

Conditions: Viral Suppression of HIV Infection

Treatments: Drug: The dosage of 400mg EFV; Behavioral: Personal involved intervention strategies

Study type: Interventional

Funder types: Other

Identifiers

NCT03852849

2018ZX10721102-002

Details and patient eligibility

About

The purpose of the study is to screen the optimal intervention strategies to rapid establish the protective barriers against HIV-infection by maximally decreasing the viremia among HIV- infected patients.

Full description

Sexual transmission became the primary route of HIV transmission in China and heterosexual transmission also contributed greatly to HIV epidemic which was mostly reported in South-west rural areas. In past years, Yunnan has experienced powerful campaign of scaling-up the HIV identification as well as antrertroviral therapy.

This study will investigate how to reach the last two of HIV'90-90-90 targets': to provide antiretroviral therapy (ART) for 90% of who diagnosed HIV infection and to achieve viral suppression for 90% of those treated.

The study population consists of participants who received an newly diagnosed HIV infection within the study period. All rerolled participants will be randomized into different study group. In intervention group, medical institutions will provide patients personal involved intervention strategies which guided by frequent viral load detection, and providing of the dosage form of 400 mg EFV in their antiviral therapy.

Main assessment measures are viral suppression rate of HIV-infected patients and treatment coverage .

Enrollment: 600 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• HIV-positive participants who received an newly diagnosed HIV infection within the study period
• Having a current residential address inside of pilot site limits
• Eighteen years old or above
• HIV transmission is heterosexual contact

Exclusion criteria

• IDU
• Having severe mental disorder

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

600 participants in 3 patient groups

routine care group

No Intervention group

Description:

Medical institutions will provide patients routine care according to the national program standard.

medicine intervention group

Experimental group

Description:

The dosage of 400 mg EFV will be used in the antiviral therapy.

Treatment:

Drug: The dosage of 400mg EFV

consolidated intervention group

Experimental group

Description:

Medical institutions will provide personal involved intervention strategies as well as the providing of dosage form of 400 mgEFV in their antiviral therapy.

Treatment:

Drug: The dosage of 400mg EFV

Behavioral: Personal involved intervention strategies